Low-Intensity Extracorporeal Shockwave Therapy and Vacuum Erectile Device as a Treatment for Peyronies Disease.
Primary Purpose
Peyronie Disease
Status
Unknown status
Phase
Not Applicable
Locations
Denmark
Study Type
Interventional
Intervention
low-intensity extracorporeal shockwave therapy
Placebo LI-ESWT
Penile pump
Sponsored by
About this trial
This is an interventional treatment trial for Peyronie Disease
Eligibility Criteria
Inclusion Criteria:
- PD for more than 6 months
- Penile curve greater than 30 degrees and less than 90 degrees
- Age 18-80
- No previous penile surgery
- Informed consent
- Able to speak and understand Danish
Exclusion Criteria:
- Penile curve greater than 90 degrees
- Previous surgery for PD
- Patients undergoing other interventions for PD
Sites / Locations
- Odense university hospitalRecruiting
Arms of the Study
Arm 1
Arm 2
Arm Type
Experimental
Placebo Comparator
Arm Label
Intervention
Placebo
Arm Description
Active shockwaves
Placebo shockwaves
Outcomes
Primary Outcome Measures
Change in penile curvature
Change in penile curvature from baseline to follow-up at 1,3 and 6 months. Penile curvature is measured on pictures submitted by the patient.
Secondary Outcome Measures
Change in pain score using the Visual Analogue Scale (VAS)
VAS is a subjective pain score ranging from 0-10 whereas 0 means no pain, and 10 being excruciating pain. Patients are asked to rank their average pain for the last 24 hours.
Change in Erectile function using the International Index of Erectile Function 5 (IIEF-5).
Erectile function is estimated using the IIEF-5 which is a 5 item questionnaire. Based on the patients answers a final score is merged. The definition of erectile dysfunction(ED) is; 5-7 (severe), 8-11(moderate), 12-16(mild-moderate), 17-21(mild) and 22-25 no ED.
Change in Peyronies disease questionnaire score
Questionnaire to evaluate the psychological/physical consequences of peyronies disease.
Full Information
1. Study Identification
Unique Protocol Identification Number
NCT03530540
Brief Title
Low-Intensity Extracorporeal Shockwave Therapy and Vacuum Erectile Device as a Treatment for Peyronies Disease.
Official Title
A Prospective Randomized Double Blinded Placebo Controlled Clinical Trial Evaluating the Combined Effect of Low-Intensity Extracorporeal Shockwave Therapy (LI-ESWT) and Vacuum Erectile Device Combined With Manipulation Exercises on Peyronies Disease.
Study Type
Interventional
2. Study Status
Record Verification Date
March 2019
Overall Recruitment Status
Unknown status
Study Start Date
March 13, 2018 (Actual)
Primary Completion Date
February 1, 2020 (Anticipated)
Study Completion Date
February 1, 2020 (Anticipated)
3. Sponsor/Collaborators
Responsible Party, by Official Title
Principal Investigator
Name of the Sponsor
Odense University Hospital
4. Oversight
Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
No
5. Study Description
Brief Summary
Aim The primary aim is to examine whether LI-ESWT and vacuum erectile device (VED) followed by manipulation exercises has beneficial effect on PD patients compared to a placebo group.
Primary Outcome
Peyronie's Disease Questionnaire (PDQ)
Visual Analogue Scale score (VAS)
International Index of Erectile Function 5 (IEFF-5)
Penile curve measurements (gold standard) on pictures before and after treatment
Plaque size
Method This study is designed as a prospective, randomized, double-blinded, placebo-controlled with follow-up after 1, 3 and 6 months.
A total of 50 participants who meets the inclusion criteria's will randomly be assigned to I(intervention) or C(control) group based on a randomization list which is retained in a sealed envelope. The content of the envelope is only familiar to the Head of the Department of Urology to ensure valid randomization.
All treatment sessions are executed at the outpatient clinic of the department of urology department L at Odense University Hospital(OUH). All patients receive treatment with the same device a Duolith® SD1 T-Top from Storz Medical. However, when treating patients in the control group the handpiece will be covered by a shockwave absorbent material. Settings and setup are identical in both groups to make sure that patients are unable to acknowledge which treatment is being performed.
6. Conditions and Keywords
Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Peyronie Disease
7. Study Design
Primary Purpose
Treatment
Study Phase
Not Applicable
Interventional Study Model
Parallel Assignment
Masking
ParticipantInvestigator
Allocation
Randomized
Enrollment
50 (Anticipated)
8. Arms, Groups, and Interventions
Arm Title
Intervention
Arm Type
Experimental
Arm Description
Active shockwaves
Arm Title
Placebo
Arm Type
Placebo Comparator
Arm Description
Placebo shockwaves
Intervention Type
Device
Intervention Name(s)
low-intensity extracorporeal shockwave therapy
Intervention Description
Active shockwaves
Intervention Type
Device
Intervention Name(s)
Placebo LI-ESWT
Intervention Description
Placebo shockwaves
Intervention Type
Device
Intervention Name(s)
Penile pump
Intervention Description
both groups will be treated with a penile pump
Primary Outcome Measure Information:
Title
Change in penile curvature
Description
Change in penile curvature from baseline to follow-up at 1,3 and 6 months. Penile curvature is measured on pictures submitted by the patient.
Time Frame
penile curve will be assessed at baseline, and 1,3 and 6 months.
Secondary Outcome Measure Information:
Title
Change in pain score using the Visual Analogue Scale (VAS)
Description
VAS is a subjective pain score ranging from 0-10 whereas 0 means no pain, and 10 being excruciating pain. Patients are asked to rank their average pain for the last 24 hours.
Time Frame
VAS will be assessed at baseline, and 1,3 and 6 months.
Title
Change in Erectile function using the International Index of Erectile Function 5 (IIEF-5).
Description
Erectile function is estimated using the IIEF-5 which is a 5 item questionnaire. Based on the patients answers a final score is merged. The definition of erectile dysfunction(ED) is; 5-7 (severe), 8-11(moderate), 12-16(mild-moderate), 17-21(mild) and 22-25 no ED.
Time Frame
IIEF-5 will be assessed at baseline, and 1,3 and 6 months.
Title
Change in Peyronies disease questionnaire score
Description
Questionnaire to evaluate the psychological/physical consequences of peyronies disease.
Time Frame
Peyronies disease questionnaire will be assessed at baseline, and 1,3 and 6 months.
10. Eligibility
Sex
Male
Minimum Age & Unit of Time
18 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria:
PD for more than 6 months
Penile curve greater than 30 degrees and less than 90 degrees
Age 18-80
No previous penile surgery
Informed consent
Able to speak and understand Danish
Exclusion Criteria:
Penile curve greater than 90 degrees
Previous surgery for PD
Patients undergoing other interventions for PD
Facility Information:
Facility Name
Odense university hospital
City
Odense
ZIP/Postal Code
5000
Country
Denmark
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Lars Lund, Professor
Phone
45 5140 8982
Email
Lars.Lund@rsyd.dk
12. IPD Sharing Statement
Plan to Share IPD
Undecided
Learn more about this trial
Low-Intensity Extracorporeal Shockwave Therapy and Vacuum Erectile Device as a Treatment for Peyronies Disease.
We'll reach out to this number within 24 hrs